Personalized ESA doses for anemia management in hemodialysis patients with end‐stage renal disease

James Rogers, Edward J. Gallaher and David Dingli

System Dynamics Review, 2018, vol. 34, issue 1-2, 121-153

Abstract: End‐stage renal disease (ESRD) patients receiving hemodialysis are typically anemic due to a lack of erythropoietin (EPO), a hormone required for red blood cell (RBC) production. EPO replacement therapy is complex, often resulting in oscillating hemoglobin (Hb) levels. EPO dosing protocols do not account for endogenous delays and appear to contribute to, if not cause, Hb variability. The Mayo Clinic Anemia Management System (MCAMS) is based on a physiological simulation of the production and lifespan of RBCs, driven by EPO dosage schedules. Patient‐specific parameters were found such that simulated Hb levels matched historical Hb levels in response to historical EPO doses. The calibrated model was used to identify new dosing regimens that stabilize Hb. MCAMS has been used to recommend individualized EPO dosage regimens to maintain stable Hb levels within a desired target range for more than 600 patients, improving patient outcomes while reducing medication costs by about 40 percent. © 2018 System Dynamics Society

Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (8)

Downloads: (external link)
https://doi.org/10.1002/sdr.1606

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bla:sysdyn:v:34:y:2018:i:1-2:p:121-153

Ordering information: This journal article can be ordered from
http://www.blackwell ... bs.asp?ref=0883-7066

Access Statistics for this article

More articles in System Dynamics Review from System Dynamics Society
Bibliographic data for series maintained by Wiley Content Delivery ().